NCT07236931

Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 71 (estimated)
• Sponsor: Donghua Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of selinexor-based chemotherapy-sparing regimens (including chemotherapy-free or dose-reduced approaches) in optimizing therapeutic strategies for treatment-naïve acute myeloid leukemia patients deemed unfit for intensive induction therapy. The investigation will focus on dynamic blast clearance patterns and early toxicity profiles to inform timely treatment adaptation during the critical induction window.

Conditions

• AML (Acute Myeloid Leukemia)

Interventions

Type	Name	Description
DRUG	the XAB regimen	the XAB regimen: a chemotherapy-free or low-dose chemotherapy regimen containing selinexor (X), azacitidine (A), and venetoclax (B)

Timeline

• Start date: 2025-11-20
• Primary completion: 2027-10-20
• Completion: 2028-10-20
• First posted: 2025-11-19
• Last updated: 2025-11-19

Locations

1 site across 1 country: China